Mednet Logo
HomeGastroenterology
Gastroenterology

Gastroenterology

Expert perspectives on IBD, liver disease, motility disorders, and GI diagnostic and therapeutic procedures.

Recent Discussions

How do you approach the management of a patient with an ileostomy who has recurrent prerenal AKI episodes that improve with IV fluids but worsen with each attempt to transition to oral fluids alone?

2
1 Answers

Mednet Member
Mednet Member
Nephrology · The University of Texas Health Science Center at San Antonio

This can be a difficult problem to deal with. In addition to electrolyte losses and volume depletion, these patients can have problems with caloric and micronutrient/vitamin depletion, so close collaboration with a nutritionist and gastroenterologist is important. Assuming the ileostomy can't be rev...

What would be your next line of treatment for disease control in a pediatric patient with metastatic hepatocellular carcinoma in partial response after multiple therapies?

1
3 Answers

Mednet Member
Mednet Member
Pediatric Hematology/Oncology · UCSF School of Medicine

Dear Dr. @Dr. First Last, Does the patient have an underlying hepatopathy (guessing yes, given the presence of varices)? And how old is the patient? Also - what was the AFP at diagnosis and what is it now? And what is the underlying liver function like? Final question - has the tumor been sequenced ...

Do you avoid terlipressin for patients with hepatorenal syndrome who have a serum sodium level less than 125 mEq/L?

2
2 Answers

Mednet Member
Mednet Member
Nephrology · The University of Texas Health Science Center at San Antonio

This is a good question and I'll admit I don't have much first-hand experience using terlipressin. However, terlipressin is relatively (6X) selective for V1 vs V2 receptors and is used for its vasoconstrictor actions in HRS. Although there are reports (mostly retrospective and uncontrolled case seri...

How do you approach ongoing screening for TB in patients with a history of treated latent TB, but who have ongoing use of DMARDs and/or biologics given Quantiferon testing and PPD can remain positive?

6
1 Answers

Mednet Member
Mednet Member
Infectious Disease · Cornell Medical School

Interferon-release assays (such as Quantiferon) and PPD testing do not discriminate between infection, reinfection, and prior infection with TB. However, in most developed countries, the likelihood that a patient who has once been treated for LTBI becomes reinfected and develops LTBI again is low, i...

How do you counsel patients on semaglutide or tirzepatide in light of potential cancer risks?

4
1 Answers

Mednet Member
Mednet Member
Endocrinology · Brigham And Womens Hospital Endocrinology

Use of GLP 1 RAs has sky-rocketed in recent years due to what seems to be a positive class effect on T2DM, weight loss, renal outcomes, cardiac outcomes and hepatic outcomes. I am not aware of any signals of increased malignancy risk. A brief literature review found meta-analyses showing possible be...

How do you manage copper deficiency?

2
1 Answers

Mednet Member
Mednet Member
Hematology · Rochester General Hospital

Copper supplements are available. Would need to exclude zinc excess as a cause and to discontinue zinc supplements.

How would you manage an elderly patient with type 3 achalasia who previously underwent POEM and has recurrent dysphagia, high Eckardt score, and dilated esophagus concerning for blown-out myotomy on esophagram?

4
1 Answers

Mednet Member
Mednet Member
Gastroenterology · Scripps Clinic La Jolla

This is a complex clinical scenario which requires a multi-disciplinary approach at an expert center. One of the main goals is to decipher why the patient is still having symptoms. Is the patient is having symptoms due to persistent achalasia or due to the blown out myotomy. You can make this distin...

In a patient with well-controlled ulcerative colitis on tofacitinib for several years, would you consider switching to upadacitinib for a more favorable side effect profile?

2
2 Answers

Mednet Member
Mednet Member
Gastroenterology · Mayo Clinic

We usually do not change away from a medication to which the patient is having a sustained response without AE. Upadacitinib is a selective Jak but same class as tofacitinib and it is unclear how much if any of a difference there is between the two in terms of AE.

When do you consider de-escalation from combination therapy with anti-TNFs and thiopurines to monotherapy with anti-TNFs in patients with IBD?

2
1 Answers

Mednet Member
Mednet Member
Gastroenterology · Mayo Clinic

I withdraw the thiopurine if after 1 year the patient has achieved the goals of care.

Would you consider chemo-RT for duodenal adenocarcinoma s/p resection with at least 1 cm positive margin in a patient with a history of Crohn's disease?

1
1 Answers

Mednet Member
Mednet Member
Radiation Oncology · Sunnybrook Health Sciences Centre

I would not offer radiation in this scenario, especially if the patient has had multiple resections for Crohn's disease. There is no real data to guide adjuvant radiotherapy in duodenal cancer, but we borrow and extrapolate from other sites and rely on first principles to offer adjuvant treatment. H...